医学
交叉研究
麻醉
刺激
颏舌
多导睡眠图
睡眠(系统调用)
阻塞性睡眠呼吸暂停
呼吸暂停
物理疗法
心脏病学
内科学
病理
替代医学
操作系统
计算机科学
安慰剂
作者
Xiaofeng Wu,Dong Zhao,Weihua Hu,Zhishui Zheng,Shiqian Zha,Qingfeng Zhang,Ke Hu
出处
期刊:Thorax
[BMJ]
日期:2022-09-07
卷期号:78 (7): 713-720
被引量:6
标识
DOI:10.1136/thorax-2021-218277
摘要
Purpose Continuous transcutaneous electrical stimulation (CTES) of the genioglossus muscle may benefit patients with obstructive sleep apnoea (OSA). However, the therapeutic value of intermittent transcutaneous electrical stimulation (ITES) for OSA is unclear. Methods This was a randomised, controlled, crossover study to compare the effects of ITES and CTES of the genioglossus muscle. Over three single-night sessions, participants were alternately subjected to three genioglossus stimulation modalities during sleep (sham, CTES and ITES). The apnoea-hypopnoea index (AHI) and oxygen desaturation index (ODI) were used for OSA diagnosis and to evaluate efficacy. A responder was defined as an individual with a ≥50% reduction in AHI together with <10 AHI events per hour and/or an ODI reduction of ≥25% between sham stimulation and electrical stimulation nights. Results Fifteen men with OSA completed the study. Compared with sham, the median AHI with ITES decreased by 13.3 events/hour (95% CI 3.1 to 23.5, p=0.030) and by 7.3 events/hour (95% CI −3.9 to 18.5, p=0.825) with CTES. The median ODI was reduced by 9.25 events/hour (95% CI 0.5 to 18.0) with ITES and 3.3 events/hour (95% CI −5.6 to 12.2) with CTES; however, there was no significant difference between groups. Furthermore, ITES outperformed CTES with respect to longest apnoea duration (median (95% CI), 9.5 (0.0 to 19.0), p=0.011)) and the highest sleep efficiency (12.2 (2.7 to 21.7), p=0.009). Of the 15 participants, 8 responded to ITES and 3 responded to CTES (p=0.058), of whom all eight cases and two out of three cases had ODIs <5 events/hour, respectively. All participants tolerated ITES well. Conclusions ITES improved upper airway obstruction in patients with OSA, suggesting that further prospective validation of the intermittent approach is warranted. Trial registration number ChiCTR2100050138.
科研通智能强力驱动
Strongly Powered by AbleSci AI